Item 8.01. Other Events.

On August 13, 2012, Santarus, Inc. ("Santarus") announced that the U.S. Food and Drug Administration ("FDA") has extended the Prescription Drug User Fee Act
("PDUFA") target action date for the review of the New Drug Application ("NDA")
for Uceris™ (budesonide) tablets 9 mg for the induction of remission of mild to moderate active ulcerative colitis from October 16, 2012 to January 16, 2013. The three-month extension is a standard extension period.

On August 3, 2012, following the FDA's request, Santarus submitted additional information for the Office of Scientific Investigations, which is the division of the FDA responsible for ensuring compliance with Good Clinical Practices ("GCP"), in connection with U.S. and ex-U.S. pre-approval inspections. On August 10, 2012, Santarus received a communication from the FDA that the submission has been classified as a major amendment to the NDA. Since the submission was received within three months of the target action date, the FDA is extending the PDUFA date by three months to provide time for a full review of the submitted information.

The FDA also indicated that if major deficiencies are not identified during the review of the NDA, the FDA plans to communicate proposed labeling and, if necessary, any postmarketing requirement/commitment requests to Santarus by December 12, 2012. Assuming FDA approval, Santarus anticipates that it will be in a position to commence the launch of Uceris approximately two months following the determination of the final product label.

A copy of the press release announcing the extension of the PDUFA target action date for the review of the NDA for Uceris is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits.

Exhibit No. Description

99.1 Press release, dated August 13, 2012

---